scholarly journals Metastatic Small-Cell Lung Cancer Presenting as Primary Adrenal Insufficiency

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Shawn Esperti ◽  
Austen Stoelting ◽  
Nicolina Scibelli ◽  
David Moccia ◽  
Dveet Patel ◽  
...  

A 40-year-old male smoker with HIV was admitted for cough, hypotension, and abdominal pain for 5 days. Chest radiography showed a right lower lobe consolidation. CT of the chest, abdomen, and pelvis revealed paratracheal adenopathy, a 5.8×4.5 cm mass invading the right bronchus intermedius, and dense bilateral adrenal masses, measuring 5.4×4.0 cm on the right and 4.8×2.0 cm on the left. Laboratory studies showed white blood cell count of 18.5 K/mm3, sodium of 131 mmol/L, creatinine of 1.6 mg/dL, and CD4 count of 567 cells/mm3. The random morning cortisol level was 7.0 μg/dL, the ACTH stimulation test yielded inappropriate response, and a random serum ACTH was elevated at 83.4 pg/mL. MRI brain revealed no pituitary adenoma confirming primary adrenal insufficiency. The adrenal CT washout study was consistent with solid mass content, concerning for metastasis. Bronchoscopy with endobronchial mass and paratracheal lymph node biopsy confirmed small-cell lung cancer (SCLC). Intravenous steroids, 100 mg hydrocortisone every 8 hours, improved his hypotension and abdominal pain. PET scan revealed metabolically active right paratracheal mass, right hilar mass, and bilateral adrenal masses. Treatment included palliative chemotherapy consisting of carboplatin/etoposide/atezolizumab and chest radiation. We present this novel case to demonstrate SCLC’s ability to cause primary adrenal insufficiency, as well as evaluate clinical response to chemotherapeutics.

Clinical Pain ◽  
2019 ◽  
Vol 18 (2) ◽  
pp. 88-91
Author(s):  
Won Jin Sung ◽  
Bo Young Hong ◽  
Joon Sung Kim ◽  
Jae Wan Yoo ◽  
Seong Hoon Lim

Immunotherapy ◽  
2020 ◽  
Author(s):  
Yasuhiro Kato ◽  
Yasutaka Watanabe ◽  
Yuki Yamane ◽  
Hideaki Mizutani ◽  
Futoshi Kurimoto ◽  
...  

Background: Tuberculosis (TB) is considered to be an adverse effect of treatment with immune checkpoint inhibitors. Methodology & results: Our case was a 75-year-old woman diagnosed with unresectable stage III non-small-cell lung cancer. After radical chemoradiotherapy was completed, durvalumab was initiated as a consolidation therapy. However, since chest CT showed appearances of infiltration shadows scattered in the periphery of the lungs after five doses of immunotherapy, duruvalumab was discontinued. 6 weeks later, the patient was aware of intermittent fever. Chest CT scan showed the appearance of a tree-in-bud pattern in the right lung. Acid-fast bacilli stain of sputum was positive and the PCR test was positive for Mycobacterium tuberculosis. Conclusion: Duruvalumab as PD-L1 blockade may activate TB.


2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Iwayemi O. Olayeye ◽  
Tulani Washington-Plaskett ◽  
Chisom J. Mbonu ◽  
Kimberly Point du Jour ◽  
Nicolas Bakinde

Sign in / Sign up

Export Citation Format

Share Document